arrow
T

Thierry Guillaume

hematology department
H指数:36
被引数:4,382

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)

急性移植物抗宿主病治疗:在糖皮质激素和鲁索利替尼之后,哪种三线治疗?(SFGM-TC)

2026-05-010
OAAI
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee

定义异基因造血细胞移植后骨髓增生异常/骨髓增生性肿瘤的缓解和复发,并优化移植结果:EBMT实践协调与指南委员会的建议

2026-04-010
PRE
Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-AML activity

NK细胞在T细胞半相合造血干细胞移植后的功能恢复:延迟的许可和较差的抗AML活性

2025-11-010
OAAI
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC

硫替派-白消安-氟达拉滨与氯法拉滨为基础的预处理方案在异基因移植联合移植后环磷酰胺治疗髓系恶性肿瘤患者中的比较:一项来自SFGM-TC的回顾性研究

2025-09-150
PRE
Proposals to develop innovation and research in cancer and optimize care for patients affected by cancer

关于发展癌症领域创新与研究的提案,以及优化受癌症影响患者的护理方案。

2025-09-010
PRE
Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation

泊沙康唑与氟康唑作为高危侵袭性真菌感染患者接受 allo-HSCT 的初始抗真菌预防

2025-04-160
PRE
Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT

欧洲异基因造血干细胞移植后供者淋巴细胞输注的当前应用:代表EBMT细胞治疗与免疫生物学工作组进行的调查

2025-03-230
PRE
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial
2024-02-197
OAAI
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
2024-01-022
PRE
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

B细胞再生障碍是同种异体造血干细胞移植受者接种BNT162b2 mRNA SARS-CoV-2疫苗后体液反应差的最有力预测指标

2022-05-0110
OAAI
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome
2021-10-0130
OAAI
Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
2021-10-010
PREAI